This company has been marked as potentially delisted and may not be actively trading. Phoenix Biotech Acquisition (PBAX) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisBuy This Stock Phoenix Biotech Acquisition Short Interest DataPhoenix Biotech Acquisition (PBAX) has a short interest of 800 shares, representing 0.08% of the float (the number of shares available for trading by the public). This marks a -69.23% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 16,686 shares to cover all short positions.Current Short Interest800 sharesPrevious Short Interest2,600 sharesChange Vs. Previous Month-69.23%Dollar Volume Sold Short$8,808.00Short Interest Ratio0.1 Days to CoverLast Record DateJanuary 31, 2024Outstanding Shares6,250,000 sharesFloat Size950,000 sharesShort Percent of Float0.08%Today's Trading Volume6,468 sharesAverage Trading Volume16,686 sharesToday's Volume Vs. Average39% Short Selling Phoenix Biotech Acquisition? Sign up to receive the latest short interest report for Phoenix Biotech Acquisition and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPBAX Short Interest Over TimePBAX Days to Cover Over TimePBAX Percentage of Float Shorted Over Time Phoenix Biotech Acquisition Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/2024800 shares $8,808.00 -69.2%0.1%0.1 $11.01 1/15/20242,600 shares $28,990.00 -10.3%0.3%1.2 $11.15 12/31/20232,900 shares $31,900.00 +61.1%0.3%1.5 $11.00 12/15/20231,800 shares $19,638.00 -5.3%0.2%0.9 $10.91 11/30/20231,900 shares $20,653.00 +46.2%0.0%4.8 $10.87 11/15/20231,300 shares $14,183.00 +8.3%0.0%4.3 $10.91 10/31/20231,200 shares $13,044.00 -7.7%0.1%3 $10.87 10/15/20231,300 shares $14,170.00 -31.6%0.1%3.3 $10.90 9/30/20231,900 shares $20,634.00 +280.0%0.1%2.4 $10.86 9/15/2023500 shares $5,400.00 -54.6%0.0%0.1 $10.80 Get the Latest News and Ratings for PBAX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Phoenix Biotech Acquisition and its competitors with MarketBeat's FREE daily newsletter. 8/31/20231,100 shares $11,891.00 +120.0%0.1%0.2 $10.81 8/15/2023500 shares $5,475.00 -37.5%0.0%0.1 $10.95 7/31/2023800 shares $8,624.00 -77.8%0.1%0.1 $10.78 7/15/20233,600 shares $38,988.00 +350.0%0.2%0.6 $10.83 6/30/2023800 shares $8,720.00 +700.0%0.1%0.1 $10.90 6/15/2023100 shares $1,081.00 -90.9%0.0%0 $10.81 5/31/20231,100 shares $11,880.00 +266.7%0.1%0.3 $10.80 5/15/2023300 shares $3,258.00 No Change0.0%0.1 $10.86 4/30/2023300 shares $3,315.00 -95.0%0.0%0.1 $11.05 4/15/20236,000 shares $64,260.00 No Change0.4%1.4 $10.71 3/31/20236,000 shares $64,080.00 -1.6%0.3%1.5 $10.68 3/15/20236,100 shares $65,148.00 -16.4%0.0%3.8 $10.68 2/28/20237,300 shares $76,869.00 -4.0%0.0%1.8 $10.53 2/15/20237,600 shares $80,636.00 +4.1%0.0%0.6 $10.61 1/31/20237,300 shares $76,796.00 -6.4%0.0%0.3 $10.52 1/15/20237,800 shares $81,354.00 -14.3%0.0%0.3 $10.43 12/30/20229,100 shares $93,459.73 -18.0%0.1%0.3 $10.27 12/15/202211,100 shares $114,330.00 +105.6%0.1%0.3 $10.30 11/30/20225,400 shares $55,296.00 -95.9%0.0%0.1 $10.24 11/15/2022130,300 shares $1.33 million +5,565.2%0.8%3.6 $10.20 10/31/20222,300 shares $23,391.00 -14.8%0.0%0.1 $10.17 10/15/20222,700 shares $27,324.00 -71.6%0.0%0.1 $10.12 9/30/20229,500 shares $95,855.00 +280.0%0.1%0.2 $10.09 9/15/20222,500 shares $25,175.00 -45.7%0.0%0 $10.07 8/31/20224,600 shares $46,322.00 +109.1%0.0%0.1 $10.07 8/15/20222,200 shares $22,198.00 -69.9%0.0%0 $10.09 7/31/20227,300 shares $73,438.00 +40.4%0.0%0.2 $10.06 7/15/20225,200 shares $52,312.00 +188.9%0.0%0.1 $10.06 6/30/20221,800 shares $18,036.00 -59.1%0.0%0 $10.02 6/15/20224,400 shares $44,132.00 -75.8%0.0%0.1 $10.03Trump to redistribute trillions of dollars (Ad)Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be laughable if it wasn’t putting so many Americans’ financial futures at severe risk… That’s why, with the 100-day mark of Trump’s second term just days away, it’s time to shine a light on what’s really going on, because if you move your money out of the wrong places and into the right ones before it’s too late… …you could be one of the few who profits from this imminent trillion-dollar reset.While everything I expose today in my latest video may seem counter to what you think you know about 5/31/202218,200 shares $182,546.00 +11.0%0.1%0.3 $10.03 5/15/202216,400 shares $164,164.00 -56.6%0.1%0.3 $10.01 4/30/202237,800 shares $378,756.00 +551.7%0.2%0.7 $10.02 4/15/20225,800 shares $58,116.00 +65.7%0.0%0.1 $10.02 3/31/20223,500 shares $35,017.50 -40.7%0.0%0.4 $10.01 3/15/20225,900 shares $58,823.00 -4.8%0.0%0.4 $9.97 2/28/20226,200 shares $61,690.00 -40.4%0.0%0.3 $9.95 2/15/202210,400 shares $103,792.00 -75.2%0.1%0.4 $9.98 1/31/202241,900 shares $415,648.00 +1,132.4%0.2%1.3 $9.92 1/15/20223,400 shares $33,728.00 +385.7%0.0%0.1 $9.92 12/31/2021700 shares $6,937.00 No ChangeN/A0 $9.91 PBAX Short Interest - Frequently Asked Questions What is Phoenix Biotech Acquisition's current short interest? Short interest is the volume of Phoenix Biotech Acquisition shares that have been sold short but have not yet been covered or closed out. As of January 31st, traders have sold 800 shares of PBAX short. 0.08% of Phoenix Biotech Acquisition's shares are currently sold short. Learn More on Phoenix Biotech Acquisition's current short interest. What is a good short interest percentage for Phoenix Biotech Acquisition? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.08% of Phoenix Biotech Acquisition's floating shares are currently sold short. Is Phoenix Biotech Acquisition's short interest increasing or decreasing? Phoenix Biotech Acquisition saw a decrease in short interest in January. As of January 31st, there was short interest totaling 800 shares, a decrease of 69.2% from the previous total of 2,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Phoenix Biotech Acquisition's float size? Phoenix Biotech Acquisition currently has issued a total of 6,250,000 shares. Some of Phoenix Biotech Acquisition's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Phoenix Biotech Acquisition currently has a public float of 950,000 shares. How does Phoenix Biotech Acquisition's short interest compare to its competitors? 0.08% of Phoenix Biotech Acquisition's shares are currently sold short. Here is how the short interest of companies in the industry of "holding & other investment offices" compare to Phoenix Biotech Acquisition: Spring Valley Acquisition Corp. II (0.02%), Plum Acquisition Corp. III (0.02%), Brooge Energy Limited (0.18%), Papaya Growth Opportunity Corp. I (0.18%), Global Lights Acquisition Corp (0.29%), Evergreen Co. (0.02%), Investcorp India Acquisition Corp (0.02%), Black Hawk Acquisition Co. (0.02%), Iron Horse Acquisitions Corp. (0.02%), byNordic Acquisition Co. (0.99%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.48 billion), General Motors ($3.85 billion), Charter Communications, Inc. ($3.38 billion), Occidental Petroleum Co. ($3.00 billion), Super Micro Computer, Inc. ($2.66 billion), Tractor Supply ($2.37 billion), Coinbase Global, Inc. ($2.25 billion), Moderna, Inc. ($2.11 billion), Royal Caribbean Cruises Ltd. ($2.06 billion), and Floor & Decor Holdings, Inc. ($1.67 billion). View all of the most shorted stocks. What does it mean to sell short Phoenix Biotech Acquisition stock? Short selling PBAX is an investing strategy that aims to generate trading profit from Phoenix Biotech Acquisition as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Phoenix Biotech Acquisition? A short squeeze for Phoenix Biotech Acquisition occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PBAX, which in turn drives the price of the stock up even further. How often is Phoenix Biotech Acquisition's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PBAX, twice per month. The most recent reporting period available is January, 31 2024. More Short Interest Resources from MarketBeat Related Companies SVII Short Squeeze PLMJ Short Squeeze BROG Short Squeeze PPYA Short Squeeze GLAC Short Squeeze EVGR Short Squeeze IVCA Short Squeeze BKHA Short Squeeze IROH Short Squeeze BYNO Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PBAX) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersIt may already be too late… A global energy shift is underway—and lithium is at the center of it. From electric vehicles to grid storage a...Huge Alerts | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredBitcoin Just Broke $100K – Are You Positioned?This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWarning: Massive IPO Predicted for May 14?The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, Ma...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phoenix Biotech Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phoenix Biotech Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.